Previous studies reported that SHMT2 can promote liver regeneration through the glycine-activated Akt/mTOR pathway (Wang et al., 2019), while a downregulated SHMT2 can suppress tumorigenesis in human hepatocellular carcinoma (Woo et al., 2016). Here, MTOR is linked to hepatocellular carcinoma.